Literature DB >> 2530459

Cerebral amyloidosis, ageing and Alzheimer's disease; a contribution from studies on Down's syndrome.

D M Mann1.   

Abstract

Observations concerning the time course of deposition of amyloid within the brain substance and blood vessels in persons, of different ages, with Down's syndrome are used to provide a perspective on the nature of the process of cerebral amyloidosis in Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2530459     DOI： 10.1016/0197-4580(89)90073-0

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  20 in total

1.  Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease.

Authors:  W Xia; J Zhang; R Perez; E H Koo; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Quantitative structure-activity relationship analysis of β-amyloid aggregation inhibitors.

Authors:  Shiri Stempler; Michal Levy-Sakin; Anat Frydman-Marom; Yaniv Amir; Roni Scherzer-Attali; Ludmila Buzhansky; Ehud Gazit; Hanoch Senderowitz
Journal:  J Comput Aided Mol Des       Date:  2010-12-17       Impact factor: 3.686

3.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

5.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells.

Authors:  B D Gitter; L M Cox; R E Rydel; P C May
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

6.  Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

Authors:  Roni Scherzer-Attali; Riccardo Pellarin; Marino Convertino; Anat Frydman-Marom; Nirit Egoz-Matia; Sivan Peled; Michal Levy-Sakin; Deborah E Shalev; Amedeo Caflisch; Ehud Gazit; Daniel Segal
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

7.  Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques.

Authors:  H Fukumoto; A Asami-Odaka; N Suzuki; H Shimada; Y Ihara; T Iwatsubo
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

Review 8.  Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain.

Authors:  Xuemin Xu
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Amyloid beta 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs.

Authors:  T Wisniewski; M Lalowski; M Bobik; M Russell; J Strosznajder; B Frangione
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

Review 10.  Molecular biology of Alzheimer's amyloid--Dutch variant.

Authors:  T Wisniewski; B Frangione
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.